-
公开(公告)号：US20250069216A2
公开(公告)日：2025-02-27
申请号：US18015021
申请日：2021-07-07
Applicant: THE GENERAL HOSPITAL CORPORATION
Inventor： Kartik Mangudi Varadarajan , Alireza Borjali , Orhun K. Muratoglu
Abstract: Systems and methods are provided for determining a clinical parameter via evaluation of sequential medical images. A sequence of at least three medical images for a patient are captured at a scanner. A set of at least two difference images are generated from the sequence of at least three medical images. Each difference image represents a difference in content between two adjacent images in the sequence of at least three medical images. The set of at least two difference images are provided to a predictive model. The predictive model includes an artificial neural network having at least one convolutional layer. A clinical parameter for the patient is determined at the predictive model from at least the set of at least two difference images.
-
公开(公告)号：US20250066494A1
公开(公告)日：2025-02-27
申请号：US18948807
申请日：2024-11-15
Applicant: The General Hospital Corporation
Inventor： Denise L. FAUSTMAN
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K47/68 , A61P31/06 , A61P31/18 , A61P35/00 , C12N5/071 , C12N7/00 , C12N15/86 , G01N33/543 , G01N33/58 , G01N33/68
Abstract: Described are antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or myeloid-derived suppressor cells (MDSCs), to expand T effector cell populations or function, and to reduce the proliferation of, or directly kill, tumor cells, such as tumor cells that express TNFR2 antigen. The polypeptides, such as antibodies and antigen-binding fragments thereof, are TNFR2 antagonists, such as dominant TNFR2 antagonists. The polypeptides can be used to suppress the T-reg- or MDSC-mediated deactivation of tumor reactive T lymphocytes, expand populations of tumor-reactive cytotoxic T cells, and/or to directly kill TNFR2+ tumor cells. The antagonistic TNFR2 polypeptides described herein can be used to treat a wide variety of cancers and infectious diseases.
-
公开(公告)号：US12208047B2
公开(公告)日：2025-01-28
申请号：US18482247
申请日：2023-10-06
Applicant: The General Hospital Corporation
Inventor： Richard R. Anderson , Mathew Avram , Fernanda H. Sakamoto , Wikunda Limpiangkanan , William A. Farinelli
IPC: A61H1/00 , A61B17/00 , A61B17/04 , A61B17/06 , A61B17/064 , A61B17/08 , A61B17/20 , A61B17/34 , A61K8/02 , A61L24/00 , A61Q19/08
Abstract: Exemplary methods and systems can be provided for resurfacing of skin that include formation of a plurality of small holes, e.g., having widths greater than about 0.2 mm and less than about 0.7 mm or 0.5 mm, using a mechanical apparatus. Compressive and/or tensile forces can then be applied to the treated region of skin as the damage heals to facilitate hole closure, and provide enhanced and/or directional shrinkage of the treated skin area.
-
公开(公告)号：US12208001B2
公开(公告)日：2025-01-28
申请号：US17731805
申请日：2022-04-28
Applicant: The General Hospital Corporation
Inventor： William G. Austen, Jr. , Michael McCormack , Robert W. Redmond , Irene E. Kochevar
IPC: A61F2/06 , A61K41/00 , A61L27/36 , A61L27/50 , A61L27/54 , A61L31/00 , A61L31/14 , A61L31/16 , A61N5/06
Abstract: A system and a method of preventing or reducing stenosis in a subject is provided. The method includes implanting a passivated graft comprising vein into an artery. The implanting of the graft replaces and/or bypasses a diseased segment of the artery. The passivated graft including vein is prepared by exposing the exterior surface of the passivated graft comprising vein to a tissue structure stabilizing agent (“TSSA”) under conditions, including irradiation with light, sufficient to promote cross-linking of proteins within the vein.
-
公开(公告)号：US12207648B2
公开(公告)日：2025-01-28
申请号：US17736700
申请日：2022-05-04
Applicant: The General Hospital Corporation
Inventor： William G. Austen, Jr. , Michael C. McCormack , Robert W. Redmond , Irene E. Kochevar
Abstract: One aspect of the invention provides a method for preparing a vein graft. The method includes: applying a tissue passivation agent to a resected anatomical vessel; placing the resected anatomical vessel in a chamber; and allowing the tissue passivation agent to cross-link while the resected anatomical vessel is in the chamber.
-
Patent Agency Ranking
公开(公告)号：US12195424B2
公开(公告)日：2025-01-14
申请号：US17456244
申请日：2021-11-23
Applicant: The General Hospital Corporation , Temple University—Of The Commonwealth System of Higher Education , Rhode Island Hospital, A Lifespan-Partner
Inventor： Frederick M. Ausubel , Wooseong Kim , Eleftherios Mylonakis , William M. Wuest
IPC: A61P31/00 , A61K31/192 , A61P31/04 , A61P31/06 , A61P31/08 , C07C39/17 , C07C65/11 , C07C65/17 , C07C235/66 , A01N31/08 , A61K31/05 , A61K45/06
Abstract: The present application provides compounds and methods of treating bacterial infection, including bacterial infection caused by P. acnes.
-
公开(公告)号：US20250012798A1
公开(公告)日：2025-01-09
申请号：US18707478
申请日：2022-11-14
Applicant: The General Hospital Corporation
Inventor： Susan Raju PAUL , Mark POZNANSKY , Ruxandra F. SIRBULESCU , James D. BERRY
IPC: G01N33/569 , A61K31/4152 , A61K31/428 , A61K45/06 , G01N15/01
Abstract: The invention features a method including characterizing a white blood cell sample from a patient using cytometry (e.g., CyTOF); wherein a deficiency in regulatory or suppressive immune cells and increased activated immune cells in the sample, relative to a healthy sample, indicates that the patient has amyotrophic lateral sclerosis (ALS).
-
公开(公告)号：US12186043B2
公开(公告)日：2025-01-07
申请号：US17316057
申请日：2021-05-10
Applicant: CANON U.S.A., INC. , The General Hospital Corporation , The Brigham and Women's Hospital Incorporated
Abstract: A control system controls an endoscope probe in manual mode or robot mode. The system comprises a handle attached to the probe; a portable display controller connectable to the handle; a robotic controller in communication with the handle and/or the portable display controller; and a support platform to which the probe and the portable device controller are attachable according to control mode. In manual mode, the handle is detached from the platform and connected to the portable display controller such that the probe is manually navigated to a first position inside a lumen. In robot mode, the handle is attached to the platform such that the robotic controller cooperates with the handle to robotically navigate the probe to a second position inside the lumen. The portable display controller includes a control section for manipulating the probe and a display section for displaying images of the lumen acquired in both modes.
-
公开(公告)号：US20250000918A1
公开(公告)日：2025-01-02
申请号：US18703879
申请日：2022-10-25
Applicant: The General Hospital Corporation
Inventor： Xue-Jun Kong
IPC: A61K35/745 , A61K9/00 , A61K35/00 , A61P1/14 , C12Q1/6874 , C12Q1/689
Abstract: The present disclosure provides a method for treating symptoms of Prader-Willi Syndrome (PWS). The method includes administering a probiotic composition to the subject. The present disclosure further includes a. method, for determining an efficacy of a probiotic composition to treat PWS in a subject. The present disclosure further includes a kit. The kit includes a probiotic composition for oral administration and a detection molecule for the detection one or more microorganisms.
-
公开(公告)号：US20240425831A1
公开(公告)日：2024-12-26
申请号：US18699164
申请日：2022-10-07
Applicant: The General Hospital Corporation
Inventor： J. Keith Joung , Julian Grünewald , Bret Miller
Abstract: Described herein are split and reduced size CRISPR Prime Editors, as well as variant reverse transcriptases, and methods of use thereof.
-
-
-
-
-
-
-
-
-
Search Results
3549
records
(took 0.043 seconds)
